jpad journal
IF 2024 : 7.8

AND option

OR option

Past issues

TOP 5 downloaded articles

Check out top downloaded articles.

 

CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS

Abstracts

J Prev Alz Dis 2015;2(4):269-396

Show summaryHide summary

No summary available.

OPEN ACCESS

Download PDF (3.03 Mo)

Read more...

CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS

Abstracts

J Prev Alz Dis 2016;4:262-379

Show summaryHide summary

No summary available.

OPEN ACCESS

Download PDF (2.87 Mo)

Read more...

DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDY

K. Kahle-Wrobleski, J.S. Andrews, M. Belger, W. Ye, S. Gauthier, D.M. Rentz, D. Galasko

J Prev Alz Dis 2017;4(2):72-80

Show summaryHide summary

Background: While functional loss forms part of the current diagnostic criteria used to identify dementia due to Alzheimer’s disease, the gradual and progressive nature of the disease makes it difficult to recognize clinically relevant signposts that could be helpful in making treatment and management decisions. Having previously observed a significant relationship between stages of functional dependence (the level of assistance patients require consequent to Alzheimer’s disease deficits, derived from the Alzheimer’s Disease Cooperative Study – Activities of Daily Living Scale) and cognitive severity, we investigated whether measures of functional dependence could be utilized to identify clinical milestones of Alzheimer’s disease progression. OBJECTIVES: To describe the patterns of change in dependence over the course of 18 months in groups stratified according to cognitive Alzheimer’s disease dementia severity (determined using the Mini-Mental State Examination score) and to identify characteristics associated with patients showing worsening dependence (progressors) versus those showing no change or improvement (non-progressors). DESIGN: Analysis of longitudinal data from the GERAS study. SETTING: GERAS is an 18-month prospective, multicenter, naturalistic, observational cohort study reflecting the routine care of patients with Alzheimer’s disease in France, Germany, and the United Kingdom. PARTICIPANTS: 1495 community-living patients, aged ≥55 years, diagnosed with probable Alzheimer’s disease dementia, and their caregivers. MEASUREMENTS: Dependence levels, cognitive function, behavioral symptoms, caregiver burden, and cost were assessed at baseline and at 18 months. RESULTS: Of 971 patients having both baseline and 18-month data, 42% (408) were progressors and 563 (58%) were non-progressors. This general pattern held for all three levels of baseline Alzheimer’s disease dementia severity – mild (Mini-Mental State Examination score 21–26), moderate (15–20) or moderately severe/severe (<15) – with 40–45% of each group identified as progressors and 55–60% as non-progressors. No baseline differences were seen between progressors and non-progressors in cognitive scores or behavioral symptoms, although progressors had significantly shorter times since diagnosis and showed milder functional impairment. Baseline factors predictive of increasing dependence over 18 months included more severe cognitive impairment, living with others, and having multiple caregivers. A higher level of initial dependence was associated with less risk of dependence progression. Total societal costs of care also increased with greater dependence. CONCLUSIONS: In this large cohort, 42% of Alzheimer’s disease dementia patients at all levels of cognitive severity became more dependent within 18 months of observation while 58% did not progress. Dependence levels may be considered as meaningful interim clinical milestones that reflect Alzheimer’s disease-related functional deficits, although a time frame that extends beyond 18 months may be necessary to observe changes if used in clinical trials or other longitudinal studies. Recognition of predictors of greater dependence offers opportunities for intervention.

CITATION:
K. Kahle-Wrobleski ; J.S. Andrews ; M. Belger ; W. Ye ; S. Gauthier ; D.M. Rentz ; D. Galasko (2017): Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer’s Disease: 18-Month Results from the GERAS Observational Study. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2017.2

OPEN ACCESS

Download PDF (293.06 Ko)View HTML

Read more...

THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION

A. Seifan, R. Isaacson

J Prev Alz Dis 2015;2(4):254-266

Show summaryHide summary

In July 2013, Weill Cornell Medical College founded the first Alzheimer’s Prevention Clinic (APC) in the United States, providing direct clinical care to family members of patients with Alzheimer’s disease (AD) as part of the Weill Cornell Memory Disorders Program. At the APC, patients seeking to lower their AD risk undergo a comprehensive assessment, receive a personalized plan based on rapidly evolving scientific evidence, and are followed over time using validated as well as emerging clinical and research technologies. The APC approach applies the principles of pharmacogenomics, nutrigenomics and clinical precision medicine, to tailor individualized therapies for patients. Longitudinal measures currently assessed in the clinic include anthropometrics, cognition, blood biomarkers (i.e., lipid, inflammatory, metabolic, nutritional) and genetics, as well as validated, self-reported measures that enable patients to track several aspects of health-related quality of life. Patients are educated on the fundamental concepts of AD prevention via an interactive online course hosted on Alzheimer’s Universe (www.AlzU.org), which also contains several activities including validated computer-based cognitive testing. The primary goal of the APC is to employ preventative measures that lower modifiable AD risk, possibly leading to a delay in onset of future symptoms. Our secondary goal is to establish a cohort of at-risk individuals who will be primed to participate in future AD prevention trials as disease-modifying agents emerge for testing at earlier stages of the AD process. The clinical services are intended to lower concern for future disease by giving patients a greater sense of control over their brain health.

CITATION:
A. Seifan ; R. Isaacson (2015): The Alzheimer’s Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2015.81

OPEN ACCESS

Download PDF (933.82 Ko)View HTML

Read more...

ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE

B. Vellas, R. Bateman, K. Blennow , G. Frisoni , K. Johnson, R. Katz , J. Langbaum, D. Marson , R. Sperling, A. Wessels, S. Salloway, R. Doody, P. Aisen, Task Force Members

J Prev Alz Dis 2015;2(2):128-135

Show summaryHide summary

For Alzheimer’s disease treatment trials that focus on the pre-dementia stage of disease, outcome measures are needed that will enable assessment of disease progression in patients who are clinically normal. The EU/US CTAD Task Force, an international collaboration of investigators from industry, academia, non-profit foundations, and regulatory agencies, met in Philadelphia, Pennsylvania, USA, on November 19, 2014 to discuss existing and novel outcome assessments that may be useful in pre-dementia trials. Composite measures that assess changes in episodic memory, executive function, global cognition, and global function have recently been developed by a number of groups and appear to be sensitive at this stage. Functional measures that involve real-life complex tasks also appear to capture early subtle changes in pre-dementia subjects and have the advantage of representing clinically meaningful change. Patient reported outcomes and novel CSF and imaging biomarkers have also shown promise. More studies are needed to validate all of these tests in the pre-dementia population. Many of them have been incorporated as exploratory measures in ongoing or planned trials.

CITATION:
B. Vellas ; R. Bateman ; K. Blennow ; G. Frisoni ; K. Johnson ; R. Katz ; J. Langbaum ; D. Marson ; R. Sperling ; A. Wessels ; S. Salloway ; R. Doody ; P. Aisen ; and Task Force Members ; (2015): Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2015.55

OPEN ACCESS

Download PDF (242.35 Ko)View HTML

Read more...

2025

JPAD Volume 12, N°05 - 2025 - See articles

 

JPAD Volume 12, N°04 - 2025 - See articles

 

JPAD Volume 12, N°03 - 2025 - See articles

 

JPAD Volume 12, N°02 - 2025 - See articles

 

JPAD Volume 12, N°01 - 2025 - See articles

 

2024

JPAD Volume 11, N°06 - 2024 - See articles

 

JPAD Volume 11, N°05 - 2024 - See articles

 

JPAD Volume 11, N°04 - 2024 - See articles

 

JPAD Volume 11, N°03 - 2024 - See articles

 

JPAD Volume 11, N°02 - 2024 - See articles

 

JPAD Volume 11, N°01 - 2024 - See articles

 

2023

JPAD Volume 10, N°04 - 2023 - See articles

 

JPAD Volume 10, N°03 - 2023 - See articles

 

JPAD Volume 10, N°02 - 2023 - See articles

 

JPAD Volume 10, N°01 - 2023 - See articles

 

2022

JPAD Volume 9, N°04 - 2022 - See articles

 

JPAD Volume 9, N°03 - 2022 - See articles

 

JPAD Volume 9, N°02 - 2022 - See articles

 

JPAD Volume 9, N°01 - 2022 - See articles

 

2021

JPAD Volume 8, N°04 - 2021 - See articles

 

JPAD Volume 8, N°03 - 2021 - See articles

 

JPAD Volume 8, N°02 - 2021 - See articles

 

JPAD Volume 8, N°01 - 2021 - See articles

 

2020

JPAD Volume 7, N°04 - 2020 - See articles

 

JPAD Volume 7, N°03 - 2020 - See articles

 

JPAD Volume 7, N°02 - 2020 - See articles

 

JPAD Volume 7, N°01 - 2020 - See articles

 

2019

JPAD Volume 6, N°04 - 2019 - See articles

 

JPAD Volume 6, N°03 - 2019 - See articles

 

JPAD Volume 6, N°02 - 2019 - See articles

 

JPAD Volume 6, N°01 - 2019 - See articles

 

2018

JPAD Volume 5, N°04 - 2018 - See articles

 

JPAD Volume 5, N°03 - 2018 - See articles

 

JPAD Volume 5, N°02 - 2018 - See articles

 

JPAD Volume 5, N°01 - 2018 - See articles

 

2017

JPAD Volume 4, N°04 - 2017 - See articles

 

JPAD Volume 4, N°03 - 2017 - See articles

 

JPAD Volume 4, N°02 - 2017 - See articles

 

JPAD Volume 4, N°01 - 2017 - See articles

 

2016

JPAD Volume 3, N°04 - 2016 - See articles

 

JPAD Volume 3, N°03 - 2016 - See articles

 

JPAD Volume 3, N°02 - 2016 - See articles

 

JPAD Volume 3, N°01 - 2016 - See articles

 

2015

JPAD Volume 2, N°04 - 2015 - See articles

 

JPAD Volume 2, N°03 - 2015 - See articles

 

JPAD Volume 2, N°02 - 2015 - See articles

 

JPAD Volume 2, N°01 - 2015 - See articles

 

2014

JPAD Volume 1, N°03 - 2014 - See articles

 

JPAD Volume 1, N°02 - 2014 - See articles

 

JPAD Volume 1, N°01 - 2014 - See articles